Local delivery of sirolimus nanoparticles for the treatment of in‐stent restenosis

• DOI: 10.1002/ccd.24331
• Publication Date: 2012-05-04T23:21:36Z
• Authors: Alexandre C. Zago; José C. Raudales; Guilherme Attizzani; Bruno S. Matte; German I. Yamamoto; Julise A. Balvedi; Ludmila Nascimento; Beatriz G. Kosach...; Paulo R. Centeno; Alcides J. Zago
• Keywords: Intravascular Ultrasound; Sirolimus; Neointima; Ferumoxytol

Objectives To test the local delivery of sirolimus nanoparticles following percutaneous transluminal coronary angioplasty (PTCA) to treat in‐stent restenosis (ISR) in a swine model. Background Coronary bare‐metal stent (BMS) implantation reduces major adverse cardiac events when compared with PTCA; however, ISR rates remain high. Methods Eighteen underwent BMS deployment guided by intravascular ultrasound (IVUS). Of these, 16 developed (1 stent/swine) and noncompliant balloon (PTCA‐NC). The animals were then randomized into four groups for infusion through porous catheter, as follows: (1) PTCA‐NC alone (control); (2) + (polylactic acid)‐based nanoparticle formulation (anionic 1); (3) (polylactic‐co‐glycolic 2); (4) Eudragit RS (cationic). angiography IVUS follow‐up performed 28 days after treatment. Results There was one episode acute occlusion cationic formulation. Late area loss similar all at according IVUS. However, luminal volume (control = 20.7%, anionic 1 4.0%, 2 6.7%, 9.6%; P 0.01) neointimal gain 68.7%, 17.4%, 29.5%, 31.2%; 0.019) significantly reduced treatment groups, especially 1. Conclusions followed safe efficacious reduce neointima this model, strategy may be promising ISR. Further studies are required validate method humans. © 2012 Wiley Periodicals, Inc.